Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 3/20 | 0.38 |
| ▸ | BACE1 | P56817 | 10/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | ALPI | P09923 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALPG | P10696 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6599258 | 0.79 | KIF11 (0.45) | KIF11 | |
| SCHEMBL3612411 | 0.78 | KIF11 (0.50) | KIF11MAPTMEN1GAAKMT2A | |
| SCHEMBL423133 | 0.78 | KIF11 (0.47) | KIF11LMNAMAPTHTTMEN1 | |
| SCHEMBL15614862 | 0.74 | AHR (0.34) | AHRBACE1 | |
| SCHEMBL12046 | 0.74 | AHR (0.50) | KIF11AHRLMNAMAPTHTT | |
| SCHEMBL2560230 | 0.74 | KIF11 (0.44) | KIF11 | |
| SCHEMBL19563466 | 0.74 | KIF11 (0.53) | KIF11 | |
| SCHEMBL18768657 | 0.74 | KIF11 (0.44) | KIF11 | |
| SCHEMBL1721979 | 0.74 | KIF11 (0.44) | KIF11 | |
| SCHEMBL9071123 | 0.74 | KIF11 (0.44) | KIF11L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153729-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-05-19 | — | — | US | disclosed |
| US-11084804-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-08-10 | — | — | US | disclosed |
| US-20210024505-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-01-28 | — | — | US | disclosed |
| EP-3696174-A1 | HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3696174-A1 | HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10626111-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190322650-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-10-24 | — | — | US | disclosed |
| US-20180282311-A9 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-10-04 | — | — | US | disclosed |
| EP-3208272-A1 | HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-3208272-A1 | HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| US-20070265345-A1 | Novel Biphenyl Compounds And Their Use | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070142460-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2007-06-21 | — | — | US | disclosed |
| WO-2007056341-A1 | HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056341-A1 | HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-1706111-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005062847-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20040152903-A1 | 6-chloro-3-pyridylmethylpropylamine derivatives, preparation process thereof and bactericides | KUREHA CORPORATION (JP) | 2004-08-05 | — | — | US | disclosed |
| EP-1375483-A1 | 6-CHLORO-3-PYRIDYLMETHYLPROPYLAMINE DERIVATIVES, PREPARATION PROCESS THEREOF AND BACTERICIDES | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265345-A1 | Novel Biphenyl Compounds And Their Use | KIF5B, KIF5C, KIF5A | KIF11 8/4885AHR 85/4885BACE1 3163/4885 |
| US-20190322650-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | KIF11 4577/4885AHR 984/4885BACE1 2256/4885 |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | CFTR, ABCC8, ABCB1 | KIF11 4792/4885AHR 533/4885BACE1 3178/4885 |
| US-20070142460-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | KIF11 824/4885AHR 4299/4885BACE1 4361/4885 |
| US-20210024505-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | KIF11 4577/4885AHR 984/4885BACE1 2256/4885 |
| US-11084804-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | KIF11 4577/4885AHR 984/4885BACE1 2256/4885 |
| US-20220153729-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | KIF11 4577/4885AHR 984/4885BACE1 2256/4885 |
| US-20040152903-A1 | 6-chloro-3-pyridylmethylpropylamine derivatives, preparation process thereof and bactericides | PGLS, TLR6, UROD | KIF11 3647/4885AHR 1535/4885BACE1 4794/4885 |
| US-10626111-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | KIF11 4538/4885AHR 1177/4885BACE1 2529/4885 |
| US-20180282311-A9 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | KIF11 4577/4885AHR 984/4885BACE1 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.